Highlights

  • BluGlass received an AUD 1.4 million second-phase photonics contract.
  • The company added an AUD 286,000 early-stage device collaboration.
  • An AUD 8 million financing facility replaced its smaller existing arrangement.
  • The developer closed September with AUD 8.66 million in cash.

BluGlass (ASX:BLG) develops and manufactures visible gallium nitride lasers for applications including defence, scientific, medical and advanced photonics markets. Its September 2026 quarterly update, released on 23 October, followed customer-funded projects through engineering and device development. New paid programs widened that work, while a larger research financing facility and a subsequent tax refund supported the commercialisation effort.

Paid Development Builds the Product Path

The company's project-to-product model used funded customer engagements to address technical requirements, demonstrate manufacturing capability and establish possible routes to future product supply.

Quarterly work covered epitaxial design and growth, device architectures, process integration, laser fabrication and packaging. Improving manufacturing repeatability and delivering customer milestones remained operating priorities.

The business also completed the third year of its work under the US Microelectronics Commons program. Multi-phase development continued with a major US defence customer, alongside collaboration with a large data-storage business. Those programs represented development activity rather than confirmation of all subsequent product orders.

A Second Phase Extends the Engineering Scope

A July contract worth AUD 1.4 million, or USD 1 million, moved an existing photonics collaboration into its second phase. The work expanded beyond initial research into additional engineering, packaging and laser integration.

The contract also included purchases of visible gallium nitride lasers. That combination connected the development work with devices supplied for the customer's platform, without establishing a separate long-term volume commitment in the quarterly update.

On 21 September, the company announced another collaboration worth approximately AUD 286,000, or USD 200,000. This early-stage feasibility program concerned a novel gallium nitride device for scientific and medical applications.

Feasibility Work Tests Process Compatibility

The new collaboration was expected to run for three to five months. It would examine whether the parties' proprietary processes could be combined for high-performance visible-wavelength lasers.

Planned tasks included evaluating device architectures, epitaxial structures, integration methods and manufacturing techniques. BluGlass contributed semiconductor laser development and epitaxy capabilities, while the customer brought photonics engineering and manufacturing expertise.

The program's feasibility stage remained important context. Its contracted value paid for defined early work; the announcement did not quantify future product revenue resulting from a successful outcome.

Financing Increases Cash but Also Adds Obligations

During September, the company agreed an AUD 8 million research and development facility to replace an AUD 2.27 million arrangement. After refinancing, it provided approximately AUD 5.4 million of additional funding liquidity.

The facility carried annual interest of 16.5% and a 2.5% establishment fee. Half the AUD 200,000 fee was capitalised into the loan and half payable in shares.

At September-end, the facility was fully drawn. Its net refinancing proceeds were already included in reported cash, so the AUD 8 million limit was not additional undrawn funding available on top of that balance.

Tax Refund Follows the Quarter-End Position

Customer receipts were AUD 1.662 million, while operating activities used AUD 3.123 million. Research expenditure excluding staff costs was AUD 1.622 million, and total staff payments were AUD 2.233 million.

Cash closed at AUD 8.66 million. After quarter-end, the company received an AUD 6.1 million FY26 research tax refund in October and applied AUD 2.75 million towards the scheduled loan repayment.

The remaining loan balance was to be repaid from the FY27 refund, no later than 1 March 2028. Customer milestones, future product conversion and working-capital discipline remained central alongside those financing commitments.